Tag Archives: IMS Health

IMS's Top 10 Pharma Social Media Engagers

The IMS Institute for Healthcare Informatics worked up a methodology for assessing the effectiveness of pharma’s social media efforts across Facebook, Twitter and YouTube, according to three indices: reach (total number of people reached through each channel via likes, shares and re-tweets); relevance (extent to which content is being shared and forwarded); and relationship (amount […]
Posted in Advertising, E-Media, leadership, Marketing, patient education, Regulatory, social media, Strategy, Technology | Tagged | 1 Comment

Drug Utilization Under Managed Medicaid

Cash-strapped states are shifting patients from traditional fee-for-service Medicaid coverage to managed Medicaid plans. The IMS Institute of Healthcare Informatics took an early look at how this trend effects prescription drug utilization.
Posted in Strategy | Also tagged , , , , , , , | Leave a comment

Obamacare's Effect on Drug Spending

Provisions in the Affordable Care Act (ACA) drove out-of-pocket costs down, while increasing drug spending among 19 to 25-year-olds in 2011, according to research published on Wednesday. The decline observed in overall out-of-pocket spending last year was the “first on record,” and was “largely related to the introduction of the ‘donut-hole’ subsidy for Medicare Part […]
Posted in FDA, healthcare, patient compliance, patient education, R&D, Regulatory, Sales, Strategy | Also tagged , , | Leave a comment

Supreme Court Strikes down Vermont Law, Upholds Rep Free Speech

June 23rd was a good day for the pharmaceutical industry. The Supreme Court released two decisions that largely went pharma’s way. There was much rejoicing across the industry, and for good reason, business as usual won out. In PLIVA v. Mensing, the Court ruled that generic drug companies should comply with federal regulations instead of […]
Posted in Legal | Also tagged , , | Leave a comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS

Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion. On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare […]
Posted in Agency Insight, Biotech, Emerging Markets, Europe, Strategy | Also tagged , | 2 Comments
  • Categories

  • Meta